Výsledky vyhledávání - "MESH: Tumor Stem Cell Assay"

Genotoxic-activated G2-M checkpoint exit is dependent on CDC25B phosphatase expression

Autor: Marie-Christine Brezak, Gregoire Prevost, Béatrix Bugler, Bernard Ducommun, Bernadette Aressy, Muriel Quaranta

Publikováno v: Molecular Cancer Therapeutics
Molecular Cancer Therapeutics, American Association for Cancer Research, 2006, 5 (6), pp.1446-51. ⟨10.1158/1535-7163.MCT-06-0099⟩

Cell cycle arrest at the G2-M checkpoint is an essential feature of the mechanisms that preserve genomic integrity. CDC25 phosphatases control cell cycle progression by dephosphorylating and activating cyclin-dependent kinase/cyclin complexes. Their

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cffe840285622d22875138ab55d19cf7
https://doi.org/10.1158/1535-7163.mct-06-0099

Zobrazit plný text záznamu

Autophagy: a novel mechanism of synergistic cytotoxicity between doxorubicin and roscovitine in a sarcoma model

Autor: Laurent Meijer, Gordon B. Mills, Khandan Keyomarsi, Donald H. Lambert, Laura A. Lambert, Na Qiao, Kelly K. Hunt

Publikováno v: Cancer Research
Cancer Research, 2008, 68 (19), pp.7966-74. ⟨10.1158/0008-5472.CAN-08-1333⟩
Cancer Research, American Association for Cancer Research, 2008, 68 (19), pp.7966-74. ⟨10.1158/0008-5472.CAN-08-1333⟩
Cancer Research, American Association for Cancer Research, 2008, 68 (19), pp.7966-74. 〈10.1158/0008-5472.CAN-08-1333〉

Doxorubicin is a genotoxic chemotherapy agent used in treatment of a wide variety of cancers. Significant clinical side effects, including cardiac toxicity and myelosuppression, severely limit the therapeutic index of this commonly used agent and met

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::264c11b00fcf711983860e67cc552593
https://europepmc.org/articles/PMC2561224/

Zobrazit plný text záznamu

Radiocurability by targeting tumor necrosis factor-alpha using a bispecific antibody in carcinoembryonic antigen transgenic mice

Autor: André Pèlegrin, Bruno Robert, David Azria, Lore Santoro, Frédéric Bibeau, Sophie Gourgou, Christel Larbouret, Pierre Martineau, Isabelle Teulon, Christine Linard, Jean-Pierre Pouget

Publikováno v: International Journal of Radiation Oncology-Biology-Physics
International Journal of Radiation Oncology-Biology-Physics, Elsevier, 2007, 69 (4), pp.1231-7. ⟨10.1016/j.ijrobp.2007.07.2372⟩
International Journal of Radiation Oncology, Biology, Physics
International Journal of Radiation Oncology, Biology, Physics, 2007, 69 (4), pp.1231-7. ⟨10.1016/j.ijrobp.2007.07.2372⟩

International audience; PURPOSE: Tumor necrosis factor-alpha (TNF-alpha) enhances radiotherapy (RT) killing of tumor cells in vitro and in vivo. To overcome systemic side effects, we used a bispecific antibody (BsAb) directed against carcinoembryonic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8ef7a0afd304a959776e1f38bf032b25
https://www.hal.inserm.fr/inserm-00225077

Zobrazit plný text záznamu

PARP inhibition sensitizes p53-deficient breast cancer cells to doxorubicin-induced apoptosis

Autor: J M Ruiz de Almodóvar, F. Javier Oliver, Ana Cañuelo, José Antonio Muñoz-Gámez, Gilbert de Murcia, David Martín-Oliva, Rocío Aguilar-Quesada, M. Isabel Núñez, M. Teresa Valenzuela

Publikováno v: Biochemical Journal
Biochemical Journal, Portland Press, 2005, 386 (Pt 1), pp.119-25. ⟨10.1042/BJ20040776⟩

p53 deficiency confers resistance to doxo (doxorubicin), a clinically active and widely used antitumour anthracycline antibiotic. The purpose of the present study was to investigate the reversal mechanism of doxo resistance by the potent PARP [poly(A

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f0e349143e197743920f1589b40effc
https://hal.archives-ouvertes.fr/hal-02371526

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání